J. Sam Lee

J. Sam Lee has an extensive work experience in the field of scientific research and development. J. Sam is currently serving as the Chief Scientific Officer at Enzychem Lifesciences since 2022, where they are responsible for the EC-18 (PLAG) Exclusive Platform Technology, focusing on anti-cancer treatment and acute radiation syndrome. Prior to this, they held the position of Chief Scientific Officer at JW CreaGene from 2020 to 2022, Union Korea Life Sciences from 2018 to 2020, and MDimune from 2016 to 2018. J. Sam also worked as a Senior Research Scientist at Primorigen Biosciences in 2015 and as a Senior Scientist at Seoul National University in 2014. Earlier in their career, they served as a Scientist at the University of Virginia from 2012 to 2014, and as a Postdoctoral Scientist at The Methodist Hospital System from 2008 to 2012. J. Sam started their career as a Research Associate at the University of Wisconsin-Madison from 2006 to 2008, and as a Research Fellow at the Korea Institute of Science and Technology from 1996 to 1999. Overall, J. Sam Lee has a diverse range of work experience in scientific research and development, with a focus on biotechnology, biomaterials, and medical imaging.

J. Sam Lee earned a Bachelor of Science (B.S.) degree in Chemistry from Kyung Hee University. Later, they received a Doctor of Philosophy (Ph.D.) in Biomedical Engineering from Wayne State University in 2006.